Brian Cost, MD
Sports Medicine · Huntsville, ALNPI 1699988048
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 277 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for sports medicine clinicians in AL, where the typical reported total is $4,051.
Across 277 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$970
- AbbVie$838
- Novo Nordisk$518
- Pfizer$236
- Corium, LLC$229
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$151
- plus $1K from 30 others
What the payments were for
- Food & beverage$4,356100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 67 | $970 |
| AbbVie(2 entities) | 60 | $838 |
| Novo Nordisk | 31 | $518 |
| Pfizer | 15 | $236 |
| Corium, LLC | 12 | $229 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $151 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $125 |
| Bayer | 6 | $124 |
| Abbott | 6 | $122 |
| Exact Sciences | 7 | $122 |
| GSK | 7 | $116 |
| Genentech USA, Inc. | 6 | $81 |
| Boehringer Ingelheim | 5 | $79 |
| Merck | 4 | $69 |
| Tolmar, Inc. | 4 | $66 |
| Antares Pharma, Inc. | 4 | $64 |
| Axsome Therapeutics, Inc. | 4 | $59 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Bausch Health US, LLC | 2 | $30 |
| AstraZeneca | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Novartis | 1 | $19 |
| Intra-sana Laboratories | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Zimmer Biomet | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Aytu Biopharma, Inc. | 1 | $12 |
| Amgen | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$4,356 in reported general payments places this provider in the 50th percentile of 108 sports medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $31,796 |
| MounjaroTirzepatide | 31 | $26,478 |
| EliquisApixaban | 28 | $20,218 |
| JardianceEmpagliflozin | 15 | $16,767 |
| MyrbetriqMirabegron | 26 | $11,644 |
| XareltoRivaroxaban | 15 | $11,412 |
| FarxigaDapagliflozin Propanediol | 15 | $10,769 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $3,587 |
| Metoprolol Succinate | 63 | $2,698 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,075 |
| Atorvastatin Calcium | 132 | $1,834 |
| Omeprazole | 101 | $1,397 |
| Rosuvastatin Calcium | 84 | $1,334 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 13 | $1,330 |
| Tamsulosin Hcl | 60 | $1,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $518 | $31,79638 claims |
| Lilly USA, LLCMounjaro | $970 | $26,47831 claims |
| PfizerEliquis | $236 | $20,21828 claims |
| Boehringer IngelheimJardiance | $79 | $16,76715 claims |
| Johnson & JohnsonXarelto | $20 | $11,41215 claims |
| AstraZenecaFarxiga | $27 | $10,76915 claims |
| AbbVieSynthroid | $838 | $70013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 108 sports medicine providers in Alabama.
Other sports medicine in Huntsville
- James McMurtrieHuntsville$54K
- Michael CantrellHuntsville$9K
- James HugheyHuntsville$3K
- Edward CainBirmingham$12.7M
- Daniel MatthewsDaphne$190K
- Mark RogersBirmingham$94K
- Amit MomayaBirmingham$77K
- Matthew SmithGuntersville$73K
- Christoper GarrettBirmingham$58K
- Jonathan IsbellHoover$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.